YSYonsu Son

Yonsu Son

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yonsu Son has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Baseline Disease Activity and Moderate-to-High Disease Activity at 6 Months in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicentre Real-World Study from the ANSWER Cohort

    by Ayaka Yoshikawa, Takuya Kotani, Wataru Yamamoto, Kenichiro Hata, Koji Nagai, Hideyuki Shiba, Yuri Hiramatsu, Yumiko Wada, Koichi Murata, Hideo Onizawa, et al.

    Background/Objectives: In rheumatoid arthritis-associated interstitial lung disease (RA-ILD), factors associated with moderate-to-high disease activity (MDA/HDA) during follow-up are not well defined. We examined baseline factors associated with MDA/HDA at 6 months. Methods: We analyzed 278 patients with RA-ILD from the multicentre ANSWER cohort. At 6 months, patients were classified by the 28-joint Disease Activity Score using erythrocyte sedimentation rate (DAS28-ESR) as remission/low disease activity (LDA) or MDA/HDA. Logistic regression used age and baseline DAS28-ESR as continuous variables (n = 178 with complete baseline DAS28-ESR); discrimination, calibration and optimism (1000 bootstrap resamples) were assessed. A sensitivity analysis used the ESR-free Clinical Disease Activity Index (CDAI) as the outcome. Results: In all, 148 patients achieved remission/LDA and 130 had MDA/HDA. Baseline DAS28-ESR was independently associated with MDA/HDA (odds ratio 2.01 per point, 95% CI 1.57–2.57), as was age (1.05 per year, 1.01–1.08). The area under the curve was 0.768 for DAS28-ESR alone and 0.776 with age added; internal validation of the two-variable model showed little estimated optimism (corrected area 0.772, calibration slope 0.984, 95% CI 0.693–1.396). With the CDAI-based outcome, the association with age was not reproduced (odds ratio 1.00, 0.97–1.04). Conclusions: Baseline disease activity is strongly associated with MDA/HDA at 6 months in RA-ILD. The incremental value of age was small, and the association with age was not reproduced when the outcome was defined by the CDAI. The age finding should therefore be regarded as secondary and dependent on the disease activity measure used. External and prospective validation is required before these findings are applied clinically.

  • Open Access

    Renal function–adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study

    by Daisuke Tomita, Yuji Nozaki, Rika Fukuda, Yumi Morimoto, Hirotaka Yamazawa, Kaori Ishimura, Chisato Ashida, Tetsu Itami, Toshihiko Shiga, Wataru Yamamoto, et al.

  • Open Access

    Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: The ANSWER cohort study

    by Yuki Etani, Yasutaka Okita, Yuichi Maeda, Kohei Tsujimoto, Takaaki Noguchi, Ryu Watanabe, Motomu Hashimoto, Iku Shirasugi, Naoki Nakano, Yuji Nozaki, et al.


  • Open Access

    Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort

    by Yuki Etani, Yasutaka Okita, Kohei Tsujimoto, Takaaki Noguchi, Koichi Murata, Takayuki Fujii, Iku Shirasugi, Mai Yamashita, Koji Nagai, Ayaka Yoshikawa, et al.

    Objectives In Japan, pharmacological treatment for rheumatoid arthritis (RA), including biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi), is provided by both orthopaedic surgeons and rheumatologists. However, differences in patient characteristics, treatment selection, and outcomes between these two clinical settings have not been fully elucidated. This study aimed to compare these factors using real-world data. Methods Using the ANSWER cohort, we identified 7268 RA treatment courses initiating bDMARDs or JAKi between August 2002 and May 2023. Patients were classified into orthopaedic surgeon–managed and rheumatologist-managed groups. Patient characteristics and treatment patterns were compared. Treatment retention due to ineffectiveness and adverse events was assessed using Cox proportional hazards models to estimate hazard ratios (HRs) adjusted for potential confounders. Results Compared with the rheumatologist-managed group, patients managed by orthopaedic surgeons had longer disease duration, higher seropositivity, greater functional impairment, although lower comorbidity prevalence such as hypertension, dyslipidemia, and diabetes mellitus. Methotrexate, tumor necrosis factor inhibitors, JAKi, and intra-articular injections were used more frequently, whereas oral glucocorticoids were used less frequently. After adjustment, treatment retention due to ineffectiveness was comparable between groups (HR 0.98, 95% CI 0.83–1.17), and changes in disease activity were similar. Discontinuation due to adverse events was significantly less frequent in the orthopaedic surgeon–managed group (HR 0.61, 95% CI 0.46–0.82). Conclusions Despite differences in patient profiles and treatment patterns, molecular-targeted therapy managed by orthopaedic surgeons achieved comparable effectiveness and was associated with a lower risk of discontinuation due to adverse events compared with rheumatology care. Key Points • Patients managed by orthopaedic surgeons had longer disease duration, higher seropositivity, and more advanced structural and functional impairment than those managed by rheumatologists. • Despite these differences, treatment effectiveness and disease activity improvement with bDMARDs or JAK inhibitors were comparable between specialties after adjustment for confounders. • Treatment discontinuation due to adverse events was less frequent in patients managed by orthopaedic surgeons. • Guideline-based management may enable consistent clinical outcomes across different specialties in real-world rheumatoid arthritis care.

  • Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in RA: the ANSWER cohort study

    by Yuhei Fujisawa, Ryu Watanabe, Tadashi Okano, Akira Onishi, Kosaku Murakami, Kosuke Ebina, Hirotaka Yamada, Mai Yamashita, Tohru Takeuchi, Ayaka Yoshikawa, et al.

    Objective: This study aimed to compare drug retention rates according to the baseline neutrophil-to-lymphocyte ratio (NLR) in patients with RA initiating biologic/targeted synthetic DMARDs (b/tsDMARDs). Methods: Data were obtained from 774 treatment courses with moderate to high disease activity at the initiation of b/tsDMARD therapy from the Kansai Multicentre ANSWER cohort. Patients were categorized into NLRlow group and NLRhigh group based on the median NLR value of 3.30. A multivariate Cox proportional hazards model, adjusted for potential confounders, was used to estimate hazard ratios (HRs) for drug retention over 2 years. Results: Patients in the NLRhigh group exhibited significantly higher baseline Clinical Disease Activity Index (CDAI) scores (P = 0.004) and more frequent glucocorticoid use (P < 0.001) than those in the NLRlow group. In the NLRlow group, drug retention rates did not significantly differ among tumour necrosis factor inhibitors (TNFi), anti-IL-6 receptor antibodies (aIL-6R), cytotoxic T lymphocyte antigen 4 immunoglobulin (CTLA4-Ig) and Janus kinase inhibitors (JAKi). In contrast, within the NLRhigh group, treatment with aIL-6R and JAKi was associated with significantly higher retention rates compared with TNFi (HR = 0.53, 95% CI: 0.32–0.88; HR = 0.36, 95% CI: 0.20–0.64, respectively). At 12 months, CDAI scores did not significantly differ among the four treatment groups in either NLR group. Conclusion: In patients with elevated baseline NLR values, aIL-6R and JAKi may offer superior drug retention compared with TNFi when initiating b/tsDMARD therapy.


  • Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study

    by Yuri Hiramatsu, Takuya Kotani, Eri Nakamura, Ayaka Yoshikawa, Motomu Hashimoto, Akira Onishi, Kouichi Murata, Natsuki Yamamoto, Kosaku Murakami, Toru Hirano, et al.

    Objectives: We evaluated real-world disease activity, treatment patterns and pregnancy outcomes in women with rheumatoid arthritis (RA) utilizing a multicentre Japanese cohort. Feasibility and impact of a treat-to-target (T2T) approach during pregnancy were also examined. Methods: A retrospective observational study analysed 118 pregnancies in patients with RA from the multicentre ANSWER cohort (2013–2023) across eight Japanese academic institutions. Clinical characteristics, treatment regimens and RA Disease Activity Scores of 28 joints based on C-reactive protein (DAS28-CRP) were assessed at preconception, during each trimester and postpartum. Pregnancy and neonatal outcomes were analysed. Results: Of 118 pregnancies, 92.8% achieved full-term deliveries (median birthweight: 2949 g). Remission or low disease activity was maintained in ∼85% of patients throughout pregnancy, with increased postpartum disease activity. Patients who continued biologic disease-modifying antirheumatic drugs (bDMARDs) during pregnancy (n = 35) exhibited significantly lower DAS28-CRP scores during the second and third trimesters compared with those who discontinued (n = 24) (P = 0.007 and P = 0.0002, respectively). Etanercept or certolizumab pegol use was associated with favourable disease control. Tocilizumab (n = 6) or abatacept (n = 2) was not associated with adverse maternal or neonatal outcomes. Glucocorticoid use was associated with increased disease activity. Salazosulfapyridine use correlated with increased birth weight (P = 0.003) and gestational age (P = 0.051). Conclusion: T2T management, including selective continuation of bDMARDs, was associated with favourable maternal disease control and reassuring pregnancy outcomes. Although the absence of long-term follow-up is a limitation, these findings provide real-world evidence supporting this approach. Larger prospective studies are required to confirm maternal and neonatal safety beyond the early postpartum.


  • Clinical efficacy of JAK inhibitors for RA patients with poor-prognosis factors: the ANSWER cohort study

    by Yuji Nozaki, Koichi Murata, Akira Onishi, Kohei Tsujimoto, Wataru Yamamoto, Hirotaka Yamada, Sho Sendo, Motomu Hashimoto, Tadashi Okano, Hideyuki Shiba, et al.

    Objectives: We evaluated the efficacy of Janus kinase inhibitors (JAKis) compared with TNF inhibitors (TNFis) in RA patients with poor-prognosis factors (PPFs), including ACPA or RF positivity, Clinical Disease Activity Index (CDAI) ≥22, CRP ≥0.6 mg/dl and HAQ-DI ≥0.5. We focused on treatment continuation, disease control and glucocorticoid (GC) reduction. Methods: We conducted a retrospective analysis of the ANSWER cohort, including 1794 RA patients treated with a TNFi (n = 1235) or JAKi (n = 559). Propensity score matching was applied to reduce bias. We categorized the patients into those with 4PPFs or <4 PPFs. Treatment persistence, CDAI changes and GC tapering over 24 months were analysed. Results: JAKi treatment demonstrated greater CDAI reduction (JAKi vs TNFi median: −23.3 vs −19.9), particularly in ACPA-positive patients. In the 4PPFs patients, JAKi treatment led to a significantly higher low disease activity achievement rate compared with TNFi (68.8% vs 60.9%) at 24 months. JAKi treatment also enabled faster GC tapering, with 72.4% discontinuation compared with 50.3% in the TNFi group at 24 months. Among the 4PPFs patients, JAKi treatment facilitated a greater (but nonsignificant) reduction in GC dosage over time. The cumulative GC discontinuation rate remained consistently higher in the JAKi group, reaching 61.3% vs 48.4% in the TNFi group at 24 months. Conclusions: JAKi treatment provided sustained disease control (especially in high-risk RA patients) and promoted GC reduction. Although TNFi remains a standard option, JAKi treatment may be preferable in patients with 4PPFs. Further research should evaluate JAKi treatment’s long-term safety and efficacy.


  • Differential Impact of Concomitant Methotrexate and Glucocorticoids Dosages on Biologics and JAK Inhibitors: The ANSWER Cohort Study

    by Kosuke Ebina, Yuki Etani, Yasutaka Okita, Kohei Tsujimoto, Yuichi Maeda, Takaaki Noguchi, Makoto Hirao, Koichi Murata, Takayuki Fujii, Motomu Hashimoto, et al.

    Aim: This multicenter retrospective study evaluated the differential impact of concomitant methotrexate (MTX) and glucocorticoids (GCs) administration by dosage on the effectiveness and safety of biological disease‐modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi) in a real‐world cohort of patients with rheumatoid arthritis, adjusting for clinical backgrounds variables. Methods: The study included 3751 treatment courses (bDMARD‐ or JAKi‐naïve cases, 48.9%; tumor necrosis factor inhibitors: 1668; tocilizumab [TCZ]: 865; abatacept [ABT]: 825; JAKi: 393). Hazard ratios for treatment retention were calculated using multivariate Cox proportional hazards models, adjusted for potential confounders. Improvement in the clinical disease activity index (ΔCDAI) with each formulation was analyzed using mixed‐effects models for repeated measures, stratified by concomitant MTX and GCs dosages. Results: Compared to MTX(−), a lower dose of MTX (< 10 mg/week) was associated with significant improvement in ΔCDAI with golimumab (GLM), TCZ, and JAKi and reduced discontinuation due to ineffectiveness of etanercept (ETN). A higher MTX dose (≥ 10 mg/week) demonstrated a similar trend. Compared to GCs(−), a lower dose of GCs (≤ 5 mg/day; prednisolone equivalent) was associated with a diminished ΔCDAI with GLM and an increased discontinuation due to ineffectiveness of ADA and GLM. A higher dose of GCs (> 5 mg/day) was associated with increased discontinuation due to safety with ETN, CZP, and JAKi. Conclusions: The effects of concomitant MTX and GCs dosages on the effectiveness and safety of biologics and JAKi vary among agents. MTX did not mitigate safety issues, and GCs did not enhance effectiveness of any agents, regardless of dosage.


  • Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER cohort

    by Kohei Tsujimoto, Kosuke Ebina, Satomi Okamura, Yasutaka Okita, Yuki Etani, Wataru Yamamoto, Akira Onishi, Hideo Onizawa, Iku Shirasugi, Naoki Nakano, et al.

    Objectives: This multicentre, retrospective study aimed to evaluate differences in drug continuation rates and efficacy between first- and second-line use of biological DMARDs (bDMARDs) and Janus kinase inhibitors (JAKi) after failure of the initial therapy in real-world RA settings. Methods: Data from an observational multicentre registry of patients with RA in Japan were analysed, encompassing 5900 treatment courses (4046 bDMARD/JAKi-naïve cases and 1854 second-line cases). Gray’s tests were used to compare the cumulative incidence function (CIF) for drug discontinuation, considering discontinuation due to remission as a competing risk. Competing risk analysis using Fine–Gray model was conducted to analyse the hazard ratios after adjusting for potential confounders. Changes in the Clinical Disease Activity Index (ΔCDAI) and disease activity score (ΔDAS28-CRP) were assessed at each time point compared with baseline using a linear mixed model with covariate adjustments. Results: Among the TNF inhibitors, IL-6 inhibitors, Cytotoxic T-lymphocyte associated protein 4 (CTLA4) and JAKi, only JAKi showed no significant difference in CIF of first- and second-line treatments. Competing risk analysis showed that consistent with the CIF analysis, second-line treatment influenced the drug continuation rates for all drugs except for JAKi. In analysing CDAI and DAS28-CRP trends using a linear mixed model, JAKi demonstrated similar efficacy as first- and second-line therapy, unlike other drugs. Conclusions: JAKi maintained continuation rates and efficacy in second-line treatment compared with first-line treatment, which is potentially advantageous over bDMARDs for patients with RA who require a change in initial therapy.


  • Open Access

    Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study

    by Yuki Etani, Yasutaka Okita, Yuichi Maeda, Kohei Tsujimoto, Makoto Hirao, Akira Onishi, Hideo Onizawa, Takaichi Okano, Keisuke Nishimura, Ayaka Yoshikawa, et al.

    Objectives: We aimed to identify the impact of rheumatoid factor (RF) or anticyclic citrullinated peptide antibody (ACPA) titres on the retention of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis. Methods: We retrospectively analysed 5312 courses of bDMARDs or JAKis from the ANSWER cohort. To calculate hazard ratios (HRs) for treatment discontinuation, we used multivariate Cox proportional hazards modelling, adjusted for potential confounders. Results: HRs for discontinuation due to ineffectiveness were calculated based on RF classification, revealing that anti-interleukin-6 receptor (aIL-6R) antibodies exhibited the highest retention rates regardless of RF titre. In the RF-positive group, tumour necrosis factor inhibitors (TNFis) showed lower retention rates, whereas cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig) and JAKis followed aIL-6R in the retention rates. When classified based on ACPA, aIL-6R also exhibited the highest retention rates across all ACPA groups. TNFis showed lower retention rates compared with other agents in the ACPA-positive group, whereas CTLA4-Ig showed lower retention rates in the ACPA-negative group compared with other agents. Conclusions: Considering effectiveness, aIL-6R showed the highest retention rates regardless of seropositivity. Although CTLA4-Ig and JAKis followed aIL-6R in RF or ACPA-positive cases, CTLA4-Ig showed the lowest retention rates in ACPA-negative cases.